The human insulin-like growth factor II gene is regulated in a development-dependent manner and is not expressed in most adult tissues. However, high levels of insulin-like growth factor II mRNA are detected in many human tumors including rhabdomyosarcoma, an embryonal tumor of skeletal muscle origin. In this study, we demonstrate that the developmentally regulated transcription factor AP-2 is expressed at higher levels in human fetal skeletal muscle and rhabdomyosarcoma cells compared to human adult skeletal muscle. Endogenous insulin-like growth factor II mRNA derived from the P3 as well as transfected P3 promoter activity were modestly and consistently increased to the same extent following treatment of the rhabdomyosarcoma cell line RD with forskolin, a compound implicated in AP-2 transactivation. This eect of AP-2 on increased transcriptional activity was con®rmed by nuclear run-on assays. Expression of AP-2B, a dominant-negative inhibitor of AP-2, suppressed the P3 promoter activity in AP-2 expressing RD cells. Furthermore, ®ve AP-2 protected regions corresponding to six AP-2 speci®c binding sites were detected in the insulin-like growth factor II P3 promoter. These data together suggest that AP-2 may contribute to the high expression of IGF-II in rhabdomyosarcoma cells.
Introduction
Insulin-like growth factor II (IGF-II) plays an important role in normal human fetal development and dierentiation. Expression of the IGF-II gene is regulated in a development-dependent and tissuespeci®c manner. There are four promoters in the IGF-II gene designated as P1 ± P4. The fetally active P3 promoter leads to expression of a 6.0 kb transcript, which has also been detected in a wide variety of tumors including rhabdomyosarcoma (RMS), a mesenchymal tumor of skeletal muscle origin (Rogler et al., 1994; Scott et al., 1985; Minniti et al., 1994) . As a mitogen, IGF-II potently stimulates cell proliferation in human tumors through an autocrine or paracrine manner (EI-Badry et al., 1989; Daughaday, 1990) .
The transcription factor AP-2 mediates transcriptional activation in response to two dierent signal transduction pathways, cAMP-dependent protein kinase A as well as phorbol-ester-and diacylglycerol-activated protein kinase C, independent of increased AP-2 mRNA and protein synthesis (Imagawa et al., 1987; Hyman et al., 1989) . Retinoic acid (RA) has been shown to be an important morphogen in vertebrate development and a potent regulator of cell dierentiation. AP-2 is also a crucial eector of RA-induced cell dierentiation (Williams et al., 1988; Luscher et al., 1989) . The temporal and spatial expression pattern of AP-2 during mouse embryogenesis is consistent with its role in regulating transcription of genes involved in the morphogenesis of neural crest and epithelial cell lineages. Expression of AP-2 is also detected in limb bud mesenchyme and meso-metanephric regions (Williams et al., 1988; Luscher et al., 1989; Mitchell et al., 1991; Byrne et al., 1994; Meier et al., 1995) . It was recently reported that AP-2 is a fundamental regulator of mammalian craniofacial development because homozygous AP-2-null mice died at or before birth as a result of severe congenital defects of the craniofacial region (Zhang et al., 1996) . In adult tissues, AP-2 appears to have a restricted and cell-type speci®c distribution (Williams et al., 1988; Kannan et al., 1994) . The 52 kD AP-2 protein functions as a dimer, recognizing a GC-rich DNA sequence present in the enhancer or promoter regions of several viral and cellular genes (Williams et al., 1988; Williams and Tijan, 1991) , such as simian virus-40 (SV40), human T-cell leukemia virus type I (HTLV-1), human metallothionin-II A (huMTII A ), human proenkephalin, collagenase, human keratin K14 genes, human insulin-like growth factor binding protein-5 (IGFBP-5), c-erbB-2, murine major histocompatibility complex (MHC) H-2K b etc. (Hyman et al., 1989; Williams et al., 1988; Bosher et al., 1995; Duan and Clemmons, 1995; Haslinger Karin, 1985; Leask et al., 1991; Lee et al., 1987; Mitchell et al., 1987; Nyborg and Dynan, 1990) . A dierentially spliced AP-2 transcript (AP-2B) derived from the AP-2 gene in a human teratocarcinoma cell line PA-1 has been cloned, and encodes a protein containing the activation domain of AP-2 and part of the DNA binding domain, but lacks the dimerization domain which is necessary for DNA binding (Buettner et al., 1993) . AP-2B is a potent negative regulator of transactivation by AP-2 through speci®cally inhibiting the interaction of AP-2 with DNA. AP-2B can suppress RA-induced growth regulation and cell dierentiation (Buettner et al., 1993) .
We have previously reported that p53 inhibited IGF-II gene expression through interfering with the binding of TATA-binding protein (TBP) to the TATA motif of P3 promoter (Zhang et al., 1996) . Defects in the function of p53 may partially contribute to the high expression of IGF-II in tumor cells. However, while virtually all RMS tumors and cell lines overexpress IGF-II, not all have alterations in p53 expression. The present study was performed to explore the potential role of AP-2 in the overexpression of IGF-II in human RMS. We demonstrate here that the cAMP inducible and developmentally regulated transcription factor AP-2 is expressed at elevated levels in the IGF-II overexpressing RMS cell lines and most RMS tumor specimens in comparison to the levels found in normal human adult skeletal muscle. AP-2 activates both endogenous and transfected IGF-II P3 promoter activities through binding to multiple AP-2 sites in the P3 promoter, which may contribute to the high expression of IGF-II in RMS cells. These studies suggest that the transcription factor AP-2 appears to have dual functions both in cell dierentiation and proliferation as previously proposed in other reports.
Results

AP-2 gene expression in RMS cells and tissues
As has been previously reported, high level IGF-II mRNA expression was noted in all cultured human RMS cell lines tested by Northern blot analysis (Figure 1 , top panel). AP-2 mRNA appearing as one major broad band at about 3.3 ± 3.6 kb ( Figure 1 , middle panel) was also expressed in all RMS cell lines. A Western blot of crude cell extracts from various RMS cell lines as well as Hela cells showed that an apparent 52-kD protein was detected in all the cell lysates as well as in the Hela cell nuclear extract (Figure 2a ). Cell lysates from human fetal skeletal muscle, two human adult skeletal muscle tissue samples and three RMS tumor specimens were also analysed by Western blot and the results are illustrated in Figure 2b . AP-2 protein was abundant in human fetal skeletal muscle (Figure 2b , lane 2) and in two out of three RMS tumors (Figure 2b , lanes 6 and 7). In contrast, there was very low or trace amount of AP-2 protein present in human adult skeletal muscle (Figure 2b, lanes 3 and 4) .
Induction of IGF-II gene expression by cAMP signal
To determine whether AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma, RD cells were incubated in 10 mM forskolin, followed by measurement of IGF-II mRNA levels. IGF-II mRNA expression in RD cells was increased about twofold following exposure to forskolin (Figure 3a and b) . This modest increase in IGF-II mRNA expression was consistent in multiple experiments and further con®rmed by RT ± PCR (data not shown). In contrast, IGF-II expression was not appreciably changed after treatment with 0.2 mM of TPA ( Figure  3a (e) P3-180Luc plasmid (3 mg) was transiently transfected into RD cells. After incubation in complete medium for 48 h, cells were incubated in serum-free medium with or without either forskolin or TPA at the same amount as above for overnight and the cellular extracts were then prepared. The luciferase activities represent the percentage ratio of treatment with either forskolin or TPA to the control group without treatment. For all transfection experiments, the results reported were obtained from at least three independent experiments each carried out in duplicate
II gene, in vitro transcript elongation (nuclear run-on) assays were performed using puri®ed RD cell nuclei following incubation with forskolin for varying time periods. As seen in Figure 3c and d, transcriptional activity increased about 1.5-fold by 3 h, 2.2-fold by 7 h and 2.3-fold by 11 h after incubation of RD cells with 10 mM forskolin. No signal was detected for the vector control sequences. In transient transfection experiments, RD cells were transfected with 3 mg of P3-180Luc for 48 h. The cells were then treated with 10 mM of forskolin overnight. The expression of luciferase was elevated about twofold (Figure 3e ), which was similar to the mRNA increase by forskolin treatment shown above. In the same transfection assay however, 0.2 mM of TPA had no signi®cant eect on luciferase activity (Figure 3e ). These results suggest that activation of the intracellular cAMP signal pathway but not the protein kinase C signal pathway could induce IGF-II mRNA expression in human RMS cells, and that the P3 Figure 4 Human IGF-II P3 promoter activity is elevated by AP-2 expression in RMS cells. (a) RD cells were transiently cotransfected with 3 mg of P3-180Luc together with an AP-2 full-length expression plasmid pSRa-AP-2 at the amounts indicated on the abscissa. The relative luciferase activities represent the ratio of luciferase activities with AP-2 expression plasmid pSRa -AP-2 to the activities with control vector pCD-SRa, [(P3-Luc+pSRa-AP-2)/(P3-Luc+pCD-SRa)]6100. The results shown are from a representative experiment that was repeated three times. (b) Similar experiment as in (a) except that P3-1300Luc was used with the indicated amounts of AP-2 plasmid. (c) P3-180Luc activation by AP-2 was compared to the activation of a mouse leptin gene promoter driven luciferase reporter, LE-Luc. Three mg of reporter genes were transiently transfected along with varying doses of AP-2 expression plasmid as indicated fragment between positions 7180 bp and +136 bp contains elements responsible for the cAMP induction.
AP-2 stimulates IGF-II P3 promoter activity
To investigate the molecular mechanisms underlying IGF-II overexpression and cAMP responsiveness in RMS cells, 3 mg of either P3-180Luc or P3-1300Luc were used to transfect RD cells together with various amounts of an AP-2 expression plasmid. Activities of both P3-180Luc and P3-1300Luc were increased by AP-2 expression in a dose-dependent manner up to 10 mg (Figure 4a and b) . When greater than 10 mg of AP-2 expression plasmid was used, the activation of P3 appeared to be saturated (data not shown). To determine the speci®city of AP-2 induced stimulation of IGF-II P3 activity, a mouse leptin gene promoter luciferase reporter (LE-Luc) was cotransfected together with the AP-2 expression plasmid (Figure 4c ). AP-2 had no eect on LE-Luc expression.
To further evaluate the role of AP-2 on IGF-II promoter activity, the eect of an AP-2 dominantnegative inhibitor, AP-2B, was also studied. Expression of AP-2B, an alternatively spliced transcript from the AP-2 gene which can speci®cally interfere with endogenous AP-2 activity, suppressed the cotransfected P3-180Luc activity ( Figure 5 ). These results suggest that endogenous AP-2 stimulates the constitutive activity of the P3 promoter.
AP-2 binds to multiple putative AP-2-like elements in the IGF-II P3 promoter
Since the cAMP pathway activator, forskolin, which is known to induce the transactivation activity of AP-2 (6, 7), elevated IGF-II gene expression and AP-2 expression increased IGF-II P3 activity as well, we analysed the P3 promoter sequence for potential AP-2 binding sites including the cis-acting DNA sequences 5'-CCCCA(G/C)(G/C)C-3' and the palindromic sequences 5'-GCCNNNGGC-3' (15, 29). Four putative AP-2 binding sites were found at positions 7121 * 7113, 7101 * 793, 753 *745 and +9 * +15. To evaluate whether AP-2 could physically bind to these sites, electrophoretic mobility shift assay was antibody was used in supershift assays (Figure 6b ). AP-2 antibody did not bind to P3 promoter directly ( Figure 6b , lane 2) but supershifted the two major bands binding to the P3 promoter. These results indicate that AP-2 can bind speci®cally to IGF-II P3 fragment.
To map the positions of AP-2 binding sites, DNase I footprinting assays were carried out using a 32 P endlabeled IGF-II P3 fragment spanning from 7180 bp to +136 bp (Figure 7) . Five regions were protected by recombinant human AP-2. A 43 bp long (7129 * 786) region contained two palindromic AP-2-like binding sites. A second and third footprinted region are 29 bp (763 * 734) and 23 bp long (72 * +25) respectively and contained palindromic AP-2-like binding sites. AP-2 also protected two regions in the 5' untranslated region (5'UTR) in which there are no well-matched consensus AP-2 binding sites. The fourth region is about 23 bp long (+44 * +67) and contains more than 90% GC bases. The ®fth region about 26 bp long (+90 * +116) is more similar to the CCCCA(G/C)(G/C)C consensus site compared to the palindromic one.
Functional characterization of the AP-2 binding sites in human IGF-II P3 promoter
Since multiple AP-2 binding sites are present in the human IGF-II P3 promoter plus 5'UTR and they were all capable of binding to the recombinant human AP-2 in vitro, we conducted studies to investigate the relative functional importance of these sites. A number of deletion derivatives, in which AP-2 binding sites had been deleted separately, were constructed (Figure 8a ) and cotransfected with various amounts of AP-2 expression plasmid in RD cells. Deletion of the 5' region from 7574 bp to 7180 bp modestly increased the basal promoter activity but had little eect on AP-2-induced activation (Figure 8a and b, P3-574Luc and P3-180Luc). Further deletions of the fragment extending from 7180 to +136 severely impaired the basal promoter activity (Figure 8a) . Removal of the region between 7180 and 7101 where the ®rst distal putative AP-2 site was located did not cause appreciable change in AP-2-induced P3-101Luc activity (Figure 8b, P3-101Luc ). This may be because the ®rst two AP-2 consensus elements are closely adjacent to each other and function together as one site. However, further deletions of either the ®rst two proximal AP-2 binding regions (Figure 8b, P3+41Luc) or the ®rst two distal binding regions (Figure 8b , P3-22Luc) or one distal plus one proximal binding region (Figure 8b , P3-88Luc) signi®cantly reduced AP-2-induced P3 promoter activity. These results suggest that all of the AP-2 binding regions in the IGF-II P3 promoter contribute to AP-2 responsiveness. Interestingly, the two AP-2 binding regions located in 5'UTR which did not contain a conserved AP-2 binding sequence also contributed to the transactivation function of AP-2.
Discussion
IGF-II appears to be an autocrine growth factor in RMS and we have been working to better understand the mechanisms leading to IGF-II overexpression in these tumors. We have now found that the transcription factor AP-2 is highly expressed in human fetal skeletal muscle tissue as well as in RMS, while expression in adult skeletal muscle is markedly lower. This ®nding is similar to previously reported studies of AP-2 expression in the mouse, where AP-2 is expressed abundantly in developing limbs during mid-embryogenesis with subsequent low or absent expression in adult mouse muscle (Mitchell et al., 1991) . Since we also found that there were several AP-2 consensus binding sites within the P3 promoter region of IGF-II, we sought to determine whether the expression of AP-2 in RMS could contribute to IGF-II overexpression in these tumors.
AP-2 is thought to mediate transcriptional activation in response to both cAMP-dependent protein kinase A as well as phorbol ester/protein kinase C pathways. We therefore evaluated the eects of these signals on IGF-II expression and IGF-II P3 activity. Following forskolin treatment of RD cells, IGF-II shown on the right, averaged over several experiments, is normalized to P3-574Luc activity which was assigned a value of 100. (b) RD cells were cotransfected with 2.5 ± 4 mg of the indicated luciferase reporter plasmids on the abscissa and 10 mg of AP-2 expression plasmid. Results shown are the ratio of luciferase activities of AP-2 expression plasmid versus the control vector alone: (P3-Luc+pSRa-AP-2)/(P3-Luc+pCD-SRa) and from at least three independent experiments each carried out in duplicate Regulation of IGF-II promoter by AP-2 L Zhang et al mRNA steady-state levels, IGF-II transcription rates, as well as transfected P3 promoter activity were increased to a similar extent. These results suggest that cAMP-induced increase in IGF-II mRNA is a transcriptionally regulated event. On the other hand, TPA treatment had no appreciable eect on IGF-II gene expression. These results suggest that only the protein kinase A pathway activates AP-2 transactivation activity in RD cells. When RD cells were transiently cotransfected with an IGF-II P3 promoter reporter and a human AP-2 expression plasmid, P3 promoter activity was markedly elevated in a wide range of doses. In addition, AP-2B, a speci®c dominant-negative inhibitor of AP-2, reduced the P3 promoter activity in RD cells. The inhibition by AP-2B suggests that endogenous AP-2 in RD cells positively regulates IGF-II P3 promoter activity. These results suggest that AP-2 is involved in regulation of human IGF-II gene expression.
In an eort to identify the sequences involved in AP-2 regulation, we have analysed the IGF-II P3 promoter region. AP-2 has been shown to bind to GC-rich sequences which vary substantially between individual AP-2 binding sites. The cis-acting DNA sequences 5'-CCCCA(G/C)(G/C)C-3' and the palindromic sequences 5'-GCCNNNGGC-3' have been considered as consensus AP-2 binding sites (Williams and Tjian 1991; Roesler et al., 1988) . The P3 promoter and 5'UTR of IGF-II gene are highly GCrich and contain multiple sequences identical to or closely related to the consensus AP-2 recognition element 5'-GCCNNNGGC-3'. DNase I footprinting experiments also identi®ed two regions protected by AP-2 protein in the 5'UTR that did not contain consensus AP-2 binding sequences. Deletion analysis of the IGF-II P3 promoter suggests that most of the AP-2 binding sites including the two variant sites in the 5'UTR contribute to AP-2-induced activation of P3 activity. The ®rst binding region in the P3 promoter harbors two AP-2 consensus elements, which may function as one site because deletion of the distal element did not appreciably change promoter activity.
It is of note that there is clearly not a direct relationship between AP-2 expression levels and IGF-II expression levels. This strongly suggests that other factors must contribute to the regulation of IGF-II mRNA expression seen in RMS.
Transcription factor OB2-1, a combination of three AP-2 family members from three AP-2 related genes termed AP-2a, AP-2b and AP-2g, has been previously shown to activate the protooncogene c-erbB-2 expression by binding to the c-erbB-2 promoter as homo-or heterodimers in human mammary-derived cell lines (Bosher et al., 1995 (Bosher et al., , 1996 . It has also been shown that AP-2 induces the Insulin-like growth factor binding protein-5 (IGFBP-5) gene expression through the proximal GCCNNNGGC-like sequences which contributes at least in part to the constitutive high expression of IGFBP-5 in ®broblasts and to the cAMP responsiveness of this gene (Duan and Clemmons, 1995) . In addition, activation of the Ras signal transduction pathway could elevate AP-2 mRNA level in human teratocarcinoma cells in culture. Constitutively high level expression of AP-2 ultimately resulted in transcriptional`self-interference', inhibition of AP-2-induced transcriptional activation, inhibition of cell dierentiation, and the transformed phenotype (Kannan et al., 1994) . Taken together, these results suggest that AP-2 may be implicated in both cell dierentiation and proliferation similar to IGF-II itself.
In summary, we have demonstrated that AP-2 mRNA and protein are present in human RMS cells which constitutively express high levels of IGF-II mRNA derived from the fetally active promoter P3. AP-2 upregulates transcription of the human IGF-II gene and likely mediates the cAMP-responsiveness by binding to multiple regions in the P3 promoter and the 5'UTR. AP-2 induction of IGF-II expression may be partially responsible for the constitutive overexpression of IGF-II in human RMS cells. It is hoped that an understanding of the molecular mechanisms underlying the constitutive overexpression of IGF-II in various human tumors may lead to the identi®cation of new therapeutic targets. The present study also demonstrates an additional role for AP-2 in human tumorigenesis beyond its crucial roles in cell dierentiation and embryonic development.
Materials and methods
cDNA clones
For transient transfection and cotransfection experiments, genomic IGF-II P3 promoter fragments of dierent lengths were subcloned at the unique SacI and HindIII sites upstream of a promoterless pGL2 luciferase reporter plasmid for the detailed plasmid construction procedures Roesler et al. (1988) . They included P3-1300Luc (from 71300 to +136), P3-574Luc (from 7574 to +136), P3-180Luc (from 7180 to +136), P3-41Luc (from 7180 to +41), P3-101Luc (from 7101 to +136), P3-88Luc (from 788 to +89), and P3-22Luc (from 722 to +136). Nucleotide +1 corresponds to the transcription start site. The human AP-2 cDNA plasmid AP-2 9b was provided by Dr Robert Tjian (Williams et al., 1988) . A 1.6 kb human AP-2 cDNA fragment was excised from AP-2 9b with EcoRI and ligated into the eukaryotic expression vector pCD-SRa (Takebe et al., 1988) , yielding the expression plasmid pSR a-AP-2 for transfection experiments. The human AP-2B expression plasmids pSG5-AP-2B were provided by Dr Michael A Tainsky (Buettner et al., 1993) and derived from the control vector pSG5 (Stratagene, La Jolla, CA, USA). The mouse leptin gene promoter (a 3 kb 5'-¯anking region of the gene) luciferase construct (LE-Luc) was provided by Dr Da-Wei Gong (Gong et al., 1996) .
Cell culture, DNA transfection, and treatment with forskolin and TPA
The human RMS cell line RD was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Human RMS cell lines, RH4 and RH5, were provided by D Shapiro (Department of Experimental Oncology, St. Jude Children's Research Hospital). The other human RMS cell lines, RH30 and CTR, were generously supplied by PJ Houghton and CP Reynolds respectively, which have been previously described (Douglass et al., 1987; Crouch et al., 1993) . Cells were grown in either DMEM or RPMI-1640 medium supplemented with 10% or 15% fetal bovine serum (FBS, Gibco ± BRL, Gaithersburg, MD, USA), 2 mM glutamine, 50 units/ml penicillin and 50 mg/ml streptomycin at 378C and 5% CO 2 in a humidi®ed incubator. In some experiments, RD cells were incubated in serum-free medium with or without either 10 mM of forskolin or 0.2 mM of 12-O-tetradecanoylphorbol-13-acetate (TPA, Sigma) overnight and then subjected to total cellular RNA isolation. Transient transfection experiments were performed as described previously (Zhang et al., 1996) . The relative luciferase activities were expressed as the percent ratio of pSG5-AP-2B to the activity of pSG5 control vector alone (pSG5-AP-2B /pSG56100). In some experiments, after incubation in complete medium for 48 h following transfection of P3-180Luc plasmid (3 mg), cells were incubated in serum-free medium with or without either 10 mM of forskolin or 0.2 mM of TPA overnight. The cellular extracts were prepared and the luciferase activity was measured as described above.
Northern blot analysis
Total RNA from cells was prepared as previously described (Zhang et al., 1996) . Following prehybridization, membranes were hybridized with a 32 P-nick-translation labeled probe using a 1.1 kb cDNA fragment from the 3' end of IGF-II exon 9 or a random-primer labeled AP-2 fragment extending from the EcoRI site at nucleotide 1 to the NcoI site at nucleotide 1289 as template, then washed as previously described (Zhang et al., 1996) . Normalization of IGF-II RNA was performed by hybridization to a 32 Pnick-translation labeled GAPDH cDNA probe. The quantitative results were obtained by screening the intensity of the autoradiographic ®lms with a computeraided image program.
